Page last updated: 2024-08-16

procarbazine and topotecan

procarbazine has been researched along with topotecan in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Blaney, SM; Burger, P; Chintagumpala, MM; Friedman, HS; Holmes, E; Horowitz, ME; Kepner, J; Kun, LE; McCluggage, C; McLendon, RE; Michalski, J; Modrich, PL; Rutka, J; Stewart, CF; Thompson, S; Woo, S1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L1

Reviews

1 review(s) available for procarbazine and topotecan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for procarbazine and topotecan

ArticleYear
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
    Journal of neuro-oncology, 2006, Volume: 77, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carrier Proteins; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Immunohistochemistry; Male; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm, Residual; Nuclear Proteins; Procarbazine; Survival Analysis; Topotecan

2006

Other Studies

3 other study(ies) available for procarbazine and topotecan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine

2010